Blockbuster drug
Sandoz challenges Bayer's Xarelto strategy in damages claim
The UK High Court does not follow Sandoz's argument that the usual calculation of lost income is insufficient for earnings lost during the ongoing PIs for a Bayer rivaroxaban patent. However, the judg
...
11 September 2025 by Christina Schulze